Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) EBITDA Margin (2020 - 2026)

GeneDx Holdings has reported EBITDA Margin over the past 7 years, most recently at 62.17% for Q1 2026.

  • Quarterly EBITDA Margin fell 5476.0% to 62.17% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 17.63% through Mar 2026, down 613.0% year-over-year, with the annual reading at 4.89% for FY2025, 1209.0% up from the prior year.
  • EBITDA Margin was 62.17% for Q1 2026 at GeneDx Holdings, down from 14.66% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 10.44% in Q2 2025 and troughed at 503.28% in Q4 2022.
  • The 5-year median for EBITDA Margin is 44.15% (2023), against an average of 87.97%.
  • Year-over-year, EBITDA Margin crashed -43375bps in 2022 and then skyrocketed 45913bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 503.28% in 2022, then surged by 91bps to 44.15% in 2023, then surged by 113bps to 5.59% in 2024, then tumbled by -362bps to 14.66% in 2025, then crashed by -324bps to 62.17% in 2026.
  • Per Business Quant, the three most recent readings for WGS's EBITDA Margin are 62.17% (Q1 2026), 14.66% (Q4 2025), and 6.38% (Q3 2025).